Looks like they've had some success with TTF in Mesothelioma. Perhaps that is what is driving their rising market cap?k
They may soon need to shift their efforts in GBM to another indication, so this is probably a good thing for them. And possibly Mesothelioma patients although I don't know enough about it to know if this offers any time of long lasting effect as they seem to have achieved 18.2 mOS compared to 12.1 mOS in historical.